Rodman & Renshaw started coverage on shares of INmune Bio (NASDAQ:INMB - Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The firm set a "buy" rating and a $23.00 price target on the stock. Rodman & Renshaw's target price indicates a potential upside of 189.64% from the company's current price.
Separately, Alliance Global Partners initiated coverage on INmune Bio in a report on Monday, October 21st. They set a "buy" rating and a $20.00 target price for the company.
View Our Latest Research Report on INmune Bio
INmune Bio Price Performance
NASDAQ INMB traded up $0.03 during trading hours on Tuesday, reaching $7.94. The company's stock had a trading volume of 251,570 shares, compared to its average volume of 484,632. The firm has a market capitalization of $176.05 million, a price-to-earnings ratio of -3.64 and a beta of 1.78. The company's 50-day moving average is $5.32 and its two-hundred day moving average is $6.05. INmune Bio has a 1-year low of $4.32 and a 1-year high of $14.74.
INmune Bio (NASDAQ:INMB - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.11). During the same period in the prior year, the firm posted ($0.48) earnings per share. Equities analysts forecast that INmune Bio will post -2.24 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of INMB. Financial Advocates Investment Management boosted its holdings in INmune Bio by 14.8% in the fourth quarter. Financial Advocates Investment Management now owns 15,500 shares of the company's stock valued at $72,000 after purchasing an additional 2,000 shares during the period. Jane Street Group LLC purchased a new stake in INmune Bio during the 3rd quarter worth about $79,000. Sanctuary Advisors LLC purchased a new stake in INmune Bio during the 3rd quarter worth about $113,000. Rhumbline Advisers purchased a new stake in INmune Bio during the 2nd quarter worth about $121,000. Finally, Barclays PLC lifted its holdings in INmune Bio by 601.9% during the 3rd quarter. Barclays PLC now owns 29,044 shares of the company's stock worth $157,000 after buying an additional 24,906 shares during the last quarter. 12.72% of the stock is currently owned by hedge funds and other institutional investors.
INmune Bio Company Profile
(
Get Free Report)
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Read More
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
